Literature DB >> 33071056

Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.

Badr Jismy1, Abdelkarim El Qami2, Anja Pišlar3, Rok Frlan3, Janko Kos4, Stanislav Gobec3, Damijan Knez5, Mohamed Abarbri6.   

Abstract

Structurally diverse heterotricyclic compounds are recognized as monoamine oxidase (MAO) inhibitors and thus represent an appealing scaffold in development and optimization of novel MAO inhibitors. Herein we explored the chemical space of pyrimido[1,2-b]indazoles as MAO inhibitors by preparing a small library of (hetero)aryl derivatives. An efficient synthetic strategy was developed starting from commercially available 1H-indazol-3-amines, which were converted to various 3-bromoheterotricyclic derivatives and further functionalized via Suzuki-Miyaura coupling reaction. Derivatives 4a-t selectively inhibited human MAO-B isoform in a reversible and competitive manner as confirmed by kinetic experiments and docking studies. Selected derivatives were not cytotoxic to neuroblastoma SH-SY5Y cells. Moreover, analogue 4i protected human neuroblastoma SH-SY5Y cells against 6-hydroxydopamine-induced cell death, which confirms the applicability of the pyrimido[1,2-b]indazoles as potential antiparkinsonian agents.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Inhibitors; Monoamine oxidase; Neuroprotection; Parkinson’s disease; Pyrimido[1,2-b]indazoles

Mesh:

Substances:

Year:  2020        PMID: 33071056     DOI: 10.1016/j.ejmech.2020.112911

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Indoleninyl-substituted pyrimido[1,2-b]indazoles via a facile condensation reaction.

Authors:  Abdul Qaiyum Ramle; Chee Chin Fei; Edward R T Tiekink; Wan Jefrey Basirun
Journal:  RSC Adv       Date:  2021-07-14       Impact factor: 3.361

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.